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Abstract
Background: Avian influenza viruses of H9N2 subtype have become highly prevalent in avian species. Although
these viruses generally cause only mild to moderate disease, they can infect a wide variety of species, including
chickens, quail, turkeys, ducks, geese, pheasant, partridge, and pigeon, even transmitted to mammalian species,
including humans, accelerating the efforts to devise protective strategies against them.
Results: The results showed that stronger immune responses were induced in a mouse model immunized with
BV-Dual-HA than in those vaccinated with a DNA vaccine encoding the same antigen. Moreover, complete
protection against lethal challenge with H9N2 virus was observed in mice.
Conclusion: BV-Dual-HA could be utilized as a vaccine candidate against H9N2 virus infection.
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Background
Influenza A viruses of the H9N2 subtype have become
highly prevalent in poultry in many countries, and
although these viruses generally cause only mild to
moderate disease, they can infect a wide variety of spe-
cies, including chickens, quail, turkeys, ducks, geese,
pheasant, partridge, and pigeon [1-4]. More importantly,
occasional transmission of H9N2 viruses from land-
based poultry to humans and pigs have been reported
[5-7]. Some investigations suggest that a significant pro-
portion of H9N2 field isolates have acquired human
virus-like receptor specificity; a few that could recognize
a 2,6-linked sialic acid (SAa2-6) have been transmitted
directly to humans [7-10]. In addition to possessing
human virus-like receptor specificity, avian H9N2
viruses induce a typical human flu-like illness, which
can easily go unreported, and therefore have the oppor-
tunity to circulate, reassort, and improve transmissibility
[7,11-14]. Hence, global concern is focused on the pre-
vention and treatment of H9N2 avian influenza virus
infections.
Prevention of avian influenza is mainly through vacci-
nation. Currently, most avian influenza vaccines used in
clinics are the inactivated type, which are propagated in
embryonated chicken eggs. However, the use of inacti-
vated avian influenza vaccines can induce little or no
cellular immune response; thus, it cannot provide wide
and persistent protection against influenza, and it will
interfere with serological monitoring. In addition, egg-
based influenza vaccine production is dependent on the
availability of embryonated eggs, which is at risk in the
event of outbreaks of avian diseases. In view of these
potential drawbacks, we sought to develop a new type of
H9N2 vaccine using the Baculovirus Dual Expression
System constructed in this study.
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The baculovirus Autographa californica multiple
nucleopolyhedrovirus (AcMNPV) has traditionally been
an excellent tool to overexpress recombinant proteins in
insect cells. Since the discovery that baculovirus is cap-
able of entering mammalian cells and mediating trans-
gene expression under the promoter active in
mammalian cells [15], baculoviral vectors have been
exploited as versatile vaccine vehicles to produce vaccine
candidates against different pathogens.
Recently, AcMNPV has been further engineered for
application as a new eukaryotic display system to
express foreign proteins on the surface of the viral
envelope [16-20] and formed a hedgehog-shaped “fake
virus”. This display system relies on the main envelope
protein of AcMNPV gp64 protein, which causes the sur-
face display of foreign proteins on the baculovirus sur-
face. This method has been extended to develop
pseudotype baculoviruses as a potential vaccine delivery
platform. Several research groups have demonstrated
that direct vaccination with this kind of pseudotype
baculoviruses can induce high titers of antigen-specific
antibodies [17,21].
Subsequently, it was determined that some natural
viral envelope proteins such as influenza hemagglutinin
(HA) can be displayed on the baculovirus surface, even
without fusion with gp64. Tang et al. [20] and Yang et
al. [19] reported that signal peptide (SP) and cytoplas-
mic tail (CT) domains of gp64 can enhance the display
of HA on the viral surface, while the transmembrane
(TM) domain of gp64 impairs HA display. Therefore, a
chimeric HA with SP and CT derived from gp64 was
chosen for our study.
Combining the characteristics of baculovirus as a gene
delivery vehicle and surface display system, we constructed
a “Baculovirus Dual Expression System,” (BV-Dual-HA),
which is capable of displaying H9N2-HA protein on the
surface of the viral envelope and expressing it upon trans-
duction in mammalian cells. The main objectives of this
study were: i) to effectively display functional HA on the
baculoviral envelope in the hope that HA would retain
superior immunogenicity upon in vivo immunization, and
ii) to efficiently express HA in transduced mammalian
cells. The results showed that stronger immune responses
were induced in a mouse model immunized with BV-
Dual-HA than in those vaccinated with a DNA vaccine
encoding the same antigen. Moreover, complete protec-
tion against lethal challenge with H9N2 virus was
observed in mice, indicating the potential of BV-Dual-HA
as a vaccine candidate against H9N2 virus infection.
Materials and methods
Animals
Six-week-old BALB/c female mice were purchased from
Southern Medicine University, Guangzhou, China, and
were housed, fed in microisolator units according to the
Veterinary guidelines of South China Agricultural Uni-
versity and all animal experiments were approved by the
South China Agricultural University Institutional Animal
Care and Use Committee.
Cell lines and virus
A porcine kidney PK-15 cell line free of PCV1 contami-
nation (ATCC CCL 33) was maintained in Dulbecco’s
modified Eagle’s medium (Invitrogen, USA) and supple-
mented with 10% (v/v) heat-inactivated fetal bovine
serum (FBS; Invitrogen, USA), 100 μg/ml of streptomy-
cin, and 100 IU/mL of penicillin. The Spodoptera frugi-
perda cells (sf9) used to propagate wild-type and
recombinant baculoviruses were cultured in Grace’s
insect media (GIBCO; Invitrogen, USA) and supplemen-
ted with 10% heat-inactivated FBS at 27°C. MDCK cells
were used to propagate avian influenza virus and were
cultured in minimal essential medium (MEM) contain-
ing 10% fetal calf serum at 37°C.
The low-pathogenicity influenza A/Chicken/Guangz-
hou/V/2008(H9N2) virus was isolated in Guangdong
Province, China. It is a mouse-adapted H9N2 strain that
can cause infection and death in mice, and was used to
challenge immunized mice in this study.
Construction of recombinant baculovirus
To construct a baculovirus transfer vector, psurf-HA, a
gene lacking the N-terminal SP and C-terminal CTD
but encoding the ectodomain of HA, was amplified
from pc-HA plasmid (a DNA vaccine was constructed
with the pcDNA3.1(+) vector expressing H9N2 HA
protein in our lab; Invitrogen) and inserted between
the sequences encoding the gp64 signal peptide and
gp64 cytoplasmic domains of a pBACsurf-1 vector
(whose gp64 ectodomain and transmembrane domain
were deleted earlier; Novagen). To construct pCMV-
surf-HA, a 2.3-kb fragment of a chimeric HA gene was
excised from psurf-HA by digestion with NheI and
HindIII, and inserted into the NheI/HindIII sites of the
pcDNA3.1(+) vector (Invitrogen). The cassette con-
sisted of the CMV-IE promoter; chimeric HA gene was
amplified by PCR and subcloned into a pFastBac™
plasmid with SalI/HindIII treatment to generate BV-
Dual-HA. The resultant BV-Dual-HA plasmid thus
contained separate HA genes driven by CMV-IE and
Pph promoters.
Recombinant baculovirus BV-Dual-HA was produced
using the Bac-to-Bac® system and was propagated in sf9
insect cells according to standard methods. Virus parti-
cles were purified by 2 rounds of sucrose gradient ultra-
centrifugation following standard protocols [22], and
infectious titers were determined with the BD BacPAK
baculovirus rapid titer kit (Clontech Laboratories, USA).
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Immunoelectron microscopy
Purified virus particles were absorbed onto carbon-
coated copper grids and incubated with a monoclonal
antibody (mAb) against HA of H9N2 (prepared in our
lab) for 1 h. The grids were incubated with goat anti-
mouse IgG labeled with 5-nm gold particles (Sigma) for
30 min. After 3 additional PBS washes, the grids were
stained with 2% phosphotungstic acid (Sigma, St. Louis,
MO, USA) and examined under transmission electron
microscopy (H-7500; Hitachi, Tokyo, Japan).
Indirect fluorescence assay
PK-15 cells were seeded at a concentration of 2.5 × 105
cells/well into 6-well tissue culture plates (Corning
Costar Co., Cambridge, MA, USA) and transduced with
purified baculovirus particles at an MOI of 10. After 48
h incubation, the cells were fixed with absolute metha-
nol for 5 min at -20°C, rinsed with PBS, and blocked
with 2% bovine serum albumin for 30 min at 37°C. The
cells were then incubated with the primary anti-body
(anti-HA mAb) for 1 h at 37°C, followed by 3 PBS
washes. The cells were then incubated with the second-
ary antibody (FITC-conjugated rabbit anti-mouse IgG;
Sigma) for 1 h at 37°C, followed by 3 PBS washes.
Fluorescence images were examined under an inverted
fluorescence microscope (Olympus IX70).
Animal experiments
Six-week-old BALB/c female mice were randomly
divided into four groups, each containing 12 mice.
Three groups were vaccinated intramuscularly (i.m.)
with 109 PFU of BV-Dual-HA, 109 PFU of wild-type
AcMNPV (AcMNPV-WT), and 100 μg of pc-HA,
respectively. On days 0 and 21. The final group was
used as the control and injected with 100 μL PBS.
Serum samples were collected on days 20 and 42 for
serological tests. On day 42, the mice were chal-
lenged intranasally (i.n.) with 50 MLD50 (50% mouse
lethal dose) of influenza A/Chicken/Guangzhou/V/
2008(H9N2) and observed for clinical signs over a
14-day period. Mice were weighed daily and exam-
ined for disease. Mice that lost more than 20% body
weight were humanely euthanized. Six days after
challenge, 3 mice from each group were sacrificed
and the lungs, brains, livers, kidneys, and spleens
were harvested to examine virus replication in SPF
embryonated eggs. The viral titer, expressed as EID50
(50% egg infection dose), was calculated by the Reed-
Muench method.
Serological testing
The hemagglutination inhibition (HI) assay and virus
neutralization (VN) assay were performed as described
previously [23].
Statistical analysis
An analysis of variance and Student’s t-test were used to
evaluate potential differences among the different
groups with regard to the humoral immune responses,
viral burdens, and body weights. Differences between
groups were considered significant at P < 0.05.
Results
Construction of baculovirus dual expression system
Construction of BV-Dual-HA is shown in Figure 1; BV-
Dual-HA harbored a gene cassette that consisted of the
gp64 signal peptide, HA ectodomain gene, HA TM,
CTD derived from gp64, and poly(A). The dual promo-
ter that consisted of the CMV immediate early enhan-
cer-promoter and the polyhedrin promoter drove
expression of the gene cassette. Thus, a chimeric HA
protein was designed to express both proteins on the
viral envelope and in mammalian cells.
As shown in Figure 2A, the HA protein expressed
with bright fluorescence could be detected by HA mAb
in BV-Dual-HA transduced cells, but not in cells trans-
duced with AcMNPV-Wt (Figure 2B), indicating that
BV-Dual-HA can enter mammalian cells efficiently and
express the HA protein.
To verify that the HA protein was displayed on the
viral envelope, purified viral particles were analyzed by
immunoelectron microscopy. As shown in Figure 2C,
specific immunogold particles were evident on the sur-
face of BV-Dual-HA, indicating the incorporation of chi-
meric HA and their display on the baculoviral envelope,
whereas no gold particles were observed on the surface
of AcMNPV-WT (Figure 2D). Moreover, incorporation
of the chimeric HA did not alter virus morphology.
Antibody responses in immunized mice
Immunization with BV-Dual-HA induced the highest
levels of H9-specific HI antibodies and VN antibodies.
At 20 days after primary immunization, all the mice
immunized with BV-Dual-HA developed detectable H9-
specific HI (Figure 3A) and VN antibodies (Figure 3B),
while the titers were very low in mice immunized with
pc-HA. Following a booster immunization, the mean
titers of HI and VN antibodies increased greatly in mice
immunized with BV-Dual-HA, and were significantly
higher than those of the mice vaccinated with pc-HA (P
< 0.01).
Protection against challenge in vaccinated mice
To evaluate the potency of the recombinant baculovirus
BV-Dual-HA against lethal influenza virus challenge, the
immunized mice were challenged with 50 MLD50 of
H9N2 V strain on day 42. Starting from day 2 post-chal-
lenge, the mice immunized with pc-HA, AcMNPV-WT,
or PBS displayed serious weight loss (Figure 4A) and
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Figure 1 Schematic representation of BV-Dual-HA structure. The gene cassette consists of the gp64 signal peptide (SP), the HA ectodomain
gene, the HA transmembrane domain (TM), gp64 cytoplasmic domain (CTD), and poly(A). The dual promoter that consisted of the CMV
immediate early enhancer/promoter (pCMV) and the polyhedrin promoter (pPH) drove expression of the gene cassette.
Figure 2 Characterization of BV-Dual-HA. PK-15 cells were transduced with BV-Dual-HA (A) or AcMNPV-WT (B) at an MOI of 10. At 48 h post-
transduction, cells were fixed with absolute methanol, and processed for indirect immunofluorescent assay. Bound antibodies were detected by
FITC-labeled anti-mouse IgG by fluorescence microscopy (green). Original magnification × 200. Electron micrograph of recombinant baculovirus
displaying HA on the viral envelope. BV-Dual-HA (C) and AcMNPV-WT (D) were treated with anti-HA monoclonal antibodies, followed by labeling
with anti-mouse IgG-gold conjugate. One end of the viral envelopes was strongly labeled with gold particles (arrows). Bars - 100 nm.
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signs of illness. In contrast, the BV-Dual-HA group only
experienced slight weight loss shortly post-challenge.
The survival rates in the BV-Dual-HA, pc-HA, and
AcMNPV-WT groups at 14 days post-challenge were
100%, 66.7%, and 75%, respectively (Figure 4B).
To determine the virus titers in tissues, 3 mice in each
group were sacrificed on day 6 post-challenge, and their
lungs, brains, kidneys, and spleens were collected for
analysis. As shown in Table 1, there were higher levels
of virus titers in the lungs of the mice immunized with
AcMNPV-WT or PBS, and virus titers were slightly
lower in the mice immunized with pc-HA. Compared
with those of the pc-HA group, no virus was detected in
the lungs of mice immunized with BV-Dual-HA. The
viral titers in the brains, kidneys, and spleens were also
analyzed, but they were much lower than that in the
lungs.
Discussion
In the present study, we developed a baculovirus dual
expression system that possesses a gene cassette consist-
ing of the chimeric HA gene under control of the
CMV-polyhedrin dual promoter. We also investigated
the efficacy of BV-Dual-HA as an avian influenza vac-
cine. Our results clearly show that immunization with
BV-Dual-HA provided 100% protection, compared to
the 66.7% and 75% protection observed with pc-HA and
AcMNPV-WT immunization, respectively. After chal-
lenge, viral titers in the lungs, brains, kidneys, and
spleens were determined on day 6 post-challenge. We
found that all mice vaccinated with BV-Dual-HA had
undetectable viral titers in these tissues, suggesting that
antibodies induced by BV-Dual-HA conferred sterilizing
immunity. Most mice vaccinated with pc-HA,
AcMNPV-WT, or PBS had detectable lung virus titers
A
B
Figure 3 Antibody responses in immunized mice with BV-Dual-HA. Mice were immunized i.m. with BV-Dual-HA, pc-HA, AcMNPV-WT or PBS.
An identical booster immunization was carried out 3 weeks later. Serum samples were collected on day 20 (red bars) and day 42 (blue bars) to
determine the HI antibody titers (A), VN antibody titers (B). All data represent the mean ± S.D.
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by day 6 post-challenge. From these results, it is obvious
that immunization with BV-Dual-HA can induce a
robust antibody response and confer complete protec-
tion against lethal virus challenge in a mouse model,
indicating that BV-Dual-HA is potential candidate vac-
cine that can prevent and control the pandemic spread
of the H9N2 influenza virus.
BV-Dual-HA is capable of displaying HA protein on
the surface of the viral envelope and expressing it upon
transduction in mammalian cells, thus playing dual roles
as a subunit/DNA vaccine, whereas pc-HA expressed
HA and functioned like a DNA vaccine. Thus, the HA
protein displayed on the envelope of BV-Dual-HA
allowed it to engage antigen presenting cells (APCs) and
A
B
Figure 4 Protective efficacy of BV-Dual-HA in mice. Mean weight loss (A) and survival (B) were evaluated for 14 days after challenge. Mean
weight loss is expressed as a percentage of original weight.
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activate the HA-specific immune reactions via the major
histocompatibility complex II-mediated antigen presen-
tation pathway, leading to more potent immune
responses. Moreover, compared with the DNA vaccine,
the baculovirus can directly transduce APCs [24,25]
resident in the muscle tissues, especially more efficient
antigen presentation to dendritic cells (DCs), which are
the most important APCs [26]. Furthermore, Martyn et
al. [27] reported that transduction by a recombinant
baculovirus was more efficient than the transfection of
conventional DNA plasmids driven by the CMV promo-
ter in both cell lines and primary cells. The transduction
of primary marmoset hepatocytes with recombinant
baculovirus was 55 times more efficient than DNA
transfection, highlighting a major advantage of recombi-
nant baculovirus for the delivery of foreign genes to
mammalian cells.
In this study, i.m. immunization of AcMNPV-WT
alone provided 75% protection from the H9N2 influenza
lethal challenge. This might be because the baculovirus
envelope protein gp64 recognizes the TLR9 molecule and
thus activates an innate immune response [28]. This is
consistent with a previous study that determined that
intranasal immunization with wild-type baculovirus alone
also provides sufficient protection from the H1N1 influ-
enza lethal challenge [29], though we didn’t evaluate the
cellular immune responses. And there are accumulated
studies have demonstrated that the baculovirus itself has
the ability to induce innate immune responses through a
signaling pathway that is dependent on Toll-like receptor
9 (TLR9)/MyD88, which results in the production of var-
ious cytokines, including members of the IFN family
[25,28,30]. Hervas-Stubbs reported that baculoviruses
have strong adjuvant properties in mice, promoting
potent humoral and CD8+ T cell adaptive responses
against co-administered antigens [30]. Besides, previously
studies also have proved that baculovirus expressing
PRRSV GP5 and M protein [31], PCV2 Cap protein [32],
H5N1 virus HA protein [33], Pseudorabies virus
glycoproteins[34] could induced a high level of IFN-g
responses. The unique ability of the baculovirus to induce
innate and adaptive immunity may have contributed to
the protection from H9N2 influenza lethal challenge.
Accumulating evidence has shown that the H9N2
virus has undergone extensive reassortment, and novel
genotypes have continued to emerge and evolve into
several clades; this may increase the likelihood of
avian-to-human interspecies transmission [10,14].
Thus, an ideal vaccine against the H9N2 avian influ-
enza virus should overcome the antigenic variability of
the virus. The baculovirus vector contains a large gen-
ome that enables insertion of large, foreign DNA frag-
ments or the construction of multivalent vaccines. In
subsequent studies, we plan to improve the protective
range of this system using appropriate selection of HA
genes derived from different clades of the H9N2 avian
influenza virus for the composition of multivalent vac-
cines. In addition, we are also ready to co-express HA
proteins and other immunogenic proteins of the H9N2
influenza virus, such as neuraminidase and M2, in
order to enhance the immune response and protective
efficiency.
Conclusion
Our study provides an alternative method of applying
the baculovirus dual expression system as an immuniz-
ing reagent against the influenza virus. Considering its
safety and cost-effectiveness, a simple scale-up would be
sufficient to produce a high-titer recombinant baculo-
virus, enabling BV-Dual-HA to be utilized as an alterna-
tive strategy to prevent and control the pandemic
spread of the H9N2 influenza virus.
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Table 1 Virus titration results of different tissue on day 6 post-challenge (log10EID50)
a
Group Virus titration results of different tissue on day 6 post-challenge (log10EID50)
b
Brain Lung Kidney Spleen
BV-Dual-HA NDc ND ND ND
pc-HA ND 4.05 ± 0.54 ND ND
AcMNPV-WT ND 4.58 ± 0.38 1.25 ND
PBS 1 ± 0.78 5.17 ± 0.29 ND ND
a Each value represents the mean of 3 mice from each group.
b Results are expressed as the EID50/0.2 mL and presented as mean ± S.D. for 3 mice.
c ND = no detection.
Lin et al. Virology Journal 2011, 8:273
http://www.virologyj.com/content/8/1/273
Page 7 of 8
Competing interests
The authors declare that they have no competing interests.
Received: 8 April 2011 Accepted: 4 June 2011 Published: 4 June 2011
References
1. Tang XY, Tian GB, Zhao CS, Zhou JF, Yu KZ: Isolation and characterization
of prevalent strains of avian influenza viruses in China. Chin J Prev Vet
Med 1998, 20:1-5.
2. Guan Y, Shortridge KF, Krauss S, Webster RG: Molecular characterization of
H9N2 influenza viruses: were they the donors of the “internal” genes of
H5N1 viruses in Hong Kong? Proc Natl Acad Sci USA 1999, 96:9363-9367.
3. Alexander DJ: A review of avian influenza in different bird species. Vet
Microbiol 2000, 74:3-13.
4. Munster VJ, Fouchier RAM: Avian influenza virus: Of virus and bird
ecology. Vaccine 2009, 27:6340-6344.
5. Peiris M, Yuen KY, Leung CW, Chan KH, Ip PL, Lai RW, Orr WK,
Shortridge KF: Human infection with influenza H9N2. Lancet 1999,
354:916-917.
6. Guo Y, Li J, Cheng X: Discovery of men infected by avian influenza A
(H9N2) virus. Chinese J Exp Clin Virol 1999, 13:105-108.
7. Peiris JSM, Guan Y, Markwell D, Ghose P, Webster RG, Shortridge KF:
Cocirculation of avian H9N2 and contemporary “human” H3N2 influenza
A viruses in pigs in southeastern China: potential for genetic
reassortment? J Virol 2001, 75:9679-9686.
8. Saito T, Lim W, Suzuki T, Suzuki Y, Kida H, Nishimura SI, Tashiro M:
Characterisation of a human H9N2 influenza virus isolated in Hong
Kong. Vaccine 2001, 20:125-133.
9. Choi YK, Ozaki H, Webby RJ, Webster RG, Peiris JS, Poon L, Butt C,
Leung YH, Guan Y: Continuing evolution of H9N2 influenza viruses in
southeastern China. J Virol 2004, 78:8609-8614.
10. Butt KM, Smith GJ, Chen H, Zhang LJ, Leung YH, Xu KM, Lim W,
Webster RG, Yuen KY, Peiris JS, Guan Y: Human infection with an avian
H9N2 influenza A virus in Hong Kong in 2003. J Clin Microbiol 2005,
43:5760-5767.
11. Li KS, Xu KM, Peiris JSM, Poon LLM, Yu KZ, Yuen KY, Shortridge KF,
Webster RG, Guan Y: Characterization of H9 subtype influenza viruses
from the ducks of southern China: a candidate for the next influenza
pandemic in humans? J Virol 2003, 77:6988-6994.
12. Xu KM, Li KS, Smith GJ, Li JW, Tai H, Zhang JX, Webster RG, Peiris JS,
Chen H, Guan Y: Evolution and molecular epidemiology of H9N2
influenza A viruses from quail in southern China, 2000 to 2005. J Virol
2007, 81:2635-2645.
13. Zhang P, Tang Y, Liu X, Liu W, Zhang X, Liu H, Peng D, Gao S, Wu Y,
Zhang L, Lu S, Liu X: A novel genotype H9N2 influenza virus possessing
human H5N1 internal genomes has been circulating in poultry in
eastern China since 1998. J Virol 2009, 83:8428-8438.
14. Sun Y, Pu J, Jiang Z, Guan T, Xia Y, Xu Q, Liu L, Ma B, Tian F, Brown EG,
Liu J: Genotypic evolution and antigenic drift of H9N2 influenza viruses
in China from 1994 to 2008. Vet Microbiol 2010, 146:215-225.
15. Hofmann C, Sandig V, Jennings G, Rudolph M, Schlag P, Strauss M: Efficient
gene-transfer into human hepatocytes by baculovirus vectors. Proc Natl
Acad Sci USA 1995, 92:10099-10103.
16. Lu L, Yu L, Kwang J: Baculovirus surface-displayed hemagglutinin of
H5N1 influenza virus sustains its authentic cleavage, hemagglutination
activity, and antigenicity. Biochem Biophys Res Commun 2007, 358:404-409.
17. Xu XG, Liu HJ: Baculovirus surface display of E2 envelope glycoprotein of
classical swine fever virus and immunogenicity of the displayed proteins
in a mouse model. Vaccine 2008, 26:5455-5460.
18. Yoshida S, Kawasaki M, Hariguchi N, Hirota K, Matsumoto M: A baculovirus
dual expression system-based malaria vaccine induces strong protection
against Plasmodium berghei sporozoite challenge in mice. Infect Immun
2009, 7:1782-1789.
19. Yang DG, Chung YC, Lai YK, Lai CW, Liu HJ, Hu YC: Avian influenza virus
hemagglutinin display on baculovirus envelope: cytoplasmic domain
affects virus properties and vaccine potential. Mol Ther 2007, 15:989-996.
20. Tang XC, Lu HR, Ross TM: Hemagglutinin displayed baculovirus protects
against highly pathogenic influenza. Vaccine 2010, 28:6821-6831.
21. Feng Q, Liu Y, Qu X, Deng H, Ding M, Lau TL, Yu AC, Chen J: Baculovirus
surface display of SARS coronavirus (SARS-CoV) spike protein and
immunogenicity of the displayed protein in mice models. DNA Cell Biol
2006, 25:668-673.
22. O’Reilly D, Miller L, Luckow V: Baculovirus expression vectors: a laboratory
manual New York and WH Freeman and Co; 1992.
23. Govorkova EA, Webby RJ, Humberd J, Seiler JP, Webster RG: Immunization
with reverse-genetics-produced H5N1 influenza vaccine protects ferrets
against homologous and heterologous challenge. J Infect Dis 2006,
194:159-167.
24. Abe T, Hemmi H, Miyamoto H, Moriishi K, Tamura S, Takaku H, Akira S,
Matsuura Y: Involvement of the toll-like receptor 9 signaling pathway in
the induction of innate immunity by baculovirus. J Virol 2005,
79:2847-2858.
25. Abe T, Kaname Y, Wen X, Tani H, Moriishi K, Uematsu S, Takeuchi O, Ishii KJ,
Kawai T, Akira S, Matsuura Y: Baculovirus induces type I interferon
production through toll-like receptor-dependent and independent
pathways in a cell-type-specific manner. J Virol 2009, 83:7629-7640.
26. Strauss R, Huser A, Ni S, Tuve S, Kiviat N, Sow PS, Hofmann C, Lieber A:
Baculovirus-based vaccination vectors allow for efficient induction of
immune responses against Plasmodium falciparum circumsporozoite
protein. Mol Ther 2007, 15:193-202.
27. Martyn JC, Dong X, Holmes-Brown S, Pribul P, Li S, Drummer HE,
Gowans EJ: Transient and stable expression of the HCV envelope
glycoproteins in cell lines and primary hepatocytes transduced with a
recombinant baculovirus. Arch Viro 2007, 152:329-343.
28. Abe T, Matsuura Y: Host innate immune responses induced by
baculovirus in mammals. Curr Gene Ther 2010, 10:226-231.
29. Abe T, Takahashi H, Hamazaki H, Miyano-Kurosaki N, Matsuura Y, Takaku H:
Baculovirus induces an innate immune response and confers protection
from lethal influenza virus infection in mice. J Immunol 2003,
171:1133-1139.
30. Hervas-Stubbs S, Rueda P, Lopez L, Leclerc C: Insect baculoviruses strongly
potentiate adaptive immune responses by inducing type I IFN. J
Immunol 2007, 178:2361-2369.
31. Wang SP, Fang LR, Fan HY, Jiang YB, Pan YF, Luo Q, Chen HC, Xiao SB:
Construction and immunogenicity of pseudotype baculovirus expressing
GP5 and M protein of porcine reproductive and respiratory syndrome
virus. Vaccine 2007, 25:8220-8227.
32. Fan HY, Pan YF, Fang LR, Wang D, Wang SP, Jiang YB, Chen HC, Xiao SB:
Construction and immunogenicity of recombinant pseudotype
baculovirus expressing the capsid protein of porcine circovirus type 2 in
mice. J Virol Methods 2008, 150:21-26.
33. Wu Q, Fang L, Wu X, Li B, Luo R, Yu Z, Jin M, Chen H, Xiao S: A
pseudotype baculovirus-mediated vaccine confers protective immunity
against lethal challenge with H5N1 avian influenza virus in mice and
chickens. Mol Immunol 2009, 13:2210-2217.
34. Grabowska AK, Lipińska AD, Rohde J, Szewczyk B, Bienkowska-Szewczyk K,
Rziha HJ: New baculovirus recombinants expressing Pseudorabies virus
(PRV) glycoproteins protect mice against lethal challenge infection.
Vaccine 2009, 27:3584-3591.
doi:10.1186/1743-422X-8-273
Cite this article as: Lin et al.: A baculovirus dual expression system-
based vaccine confers complete protection against lethal challenge
with H9N2 avian influenza virus in mice. Virology Journal 2011 8:273.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Lin et al. Virology Journal 2011, 8:273
http://www.virologyj.com/content/8/1/273
Page 8 of 8
